CIK 0001382101 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 102.5 M | 153.7 M | ||
| Net income (USD) | -119.2 M | -105.5 M | -32.1 M | |
| Diluted EPS (USD/shares) | -22.49 | -1.78 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-22 | 4 | 4 | 2026-09-18 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-12 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-12 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-12 |
| 2026-07-30 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-09 | 4 | 4 | 2026-06-05 |
| 2026-06-08 | 8-K | 8-K items 5.07 | 2026-06-05 |
| 2026-06-02 | 4 | 4 | 2026-06-02 |
| 2026-05-15 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-14 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-14 | 8-K | 8-K items 2.02,9.01 | 2026-05-14 |
| 2026-05-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-01 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-22 | ARS | ARS | 2025-12-31 |
| 2026-04-22 | DEFA14A | DEFA14A | |
| 2026-04-22 | DEF 14A | DEF 14A | 2026-06-05 |
Forms on file (last 1,000): 4 297, 8-K 92, 3 34, SC 13G/A 30, 10-Q 24, SC 13G 19, SCHEDULE 13G/A 13, S-8 12. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=STRO (0.002 USD), /gw/filings/filings?ticker=STRO&form=8-K, /gw/filings/facts?ticker=STRO&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange